After culling workforce, migraine biotech Zosano drops lead — and sole — program

It appears Zosano may not have much left in the tank.

In April, the migraine-focused biotech announced that it would cull about a third of its workforce — less than a month after the FDA refused to review the company’s resubmission for its migraine treatment patch known as M207. The agency said that the company didn’t adequately respond to the deficiencies identified in the FDA’s initial, 2020 CRL.